Biogen price target raised to $157 from $150 at HSBC

HSBC analyst Morten Herholdt raised the firm's price target on Biogen to $157 from $150 and keeps a Reduce rating on the shares. In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector's relative outperformance potential for the second half of the year, noting that the Therapeutics space offering "attractive risk weighted returns," Tools "might be the best way to play a cyclical rally," and that MedTech is "cheap."